Vibigaba (germinated brown rice) and maintenance of normal blood cholesterol concentration: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No&#160;1924/2006 by Turck, Dominique et al.
SCIENTIFIC OPINION
ADOPTED: 27 June 2017
doi: 10.2903/j.efsa.2017.4913
Vibigaba (germinated brown rice) and maintenance of
normal blood cholesterol concentration: evaluation of a
health claim pursuant to Article 13(5) of Regulation (EC)
No 1924/2006
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA),
Dominique Turck, Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait,
Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Monika Neuh€auser-Berthold, Gra _zyna Nowicka, Kristina Pentieva,
Yolanda Sanz, Anders Sj€odin, Martin Stern, Daniel Tome, Henk Van Loveren, Marco Vinceti,
Peter Willatts, Ambroise Martin, John Joseph Strain and Alfonso Siani
Abstract
Following an application from Loc Troi group, submitted for authorisation of a health claim pursuant to
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientific substantiation of a health claim related to Vibigaba (germinated brown rice) and contribution
to the maintenance of normal blood cholesterol concentrations. The scope of the application was
proposed to fall under a health claim based on newly developed scientific evidence. The food proposed
by the applicant as the subject of the health claim is Vibigaba. The Panel considers that the
germinated brown rice Vibigaba is sufficiently characterised. The claimed effect proposed by the
applicant is ‘contribution to the maintenance of normal blood cholesterol levels’. The Panel considers
that maintenance of normal blood cholesterol concentrations is a beneficial physiological effect. The
Panel notes that the applicant did not perform a comprehensive literature search to identify human
intervention studies which could be pertinent to the claim. The applicant did not reply to a specific
request from EFSA to provide this information. The applicant identified one human intervention study
as being pertinent to the claim. The Panel notes the important methodological limitations of the study
(e.g. statistical methods used for data analysis not appropriate for the study design) and that the
information provided on the design and conduct of the study is insufficient for a complete scientific
evaluation. The Panel considers that no conclusions can be drawn from this study for the scientific
substantiation of the claim. The Panel concludes that a cause and effect relationship has not been
established between the consumption of Vibigaba (germinated brown rice) and maintenance of normal
blood cholesterol concentration.
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Summary
Following an application from Loc Troi group, submitted for authorisation of a health claim pursuant
to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientific substantiation of a health claim related to Vibigaba (germinated brown rice) and contribution
to the maintenance of normal blood cholesterol concentration.
The scope of the application was proposed to fall under a health claim based on newly developed
scientific evidence.
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications and the guidance on the
scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular
health.
The food proposed by the applicant as the subject of the health claim is Vibigaba (germinated
brown rice). The Panel considers that the germinated brown rice Vibigaba, which is the subject of the
health claim, is sufficiently characterised.
The claimed effect proposed by the applicant is ‘contribution to the maintenance of normal blood
cholesterol levels’. The proposed target population is ‘adults with metabolic syndrome’. The
Panel considers that maintenance of normal blood cholesterol concentration is a beneficial physiological
effect.
The Panel notes that the applicant did not perform a comprehensive literature search to identify
human intervention studies which could be pertinent to the claim other than the one provided by the
applicant. The applicant did not reply to a specific request from the European Food Safety Authority
(EFSA) to provide this information.
The applicant identified one human intervention study as being pertinent to the claim. The
Panel notes the important methodological limitations of the study (e.g. statistical analysis not
appropriate for the study design) and that the information provided on the design and conduct of the
study is insufficient for a complete scientific evaluation. Upon a request from EFSA to provide
additional information on the study which would allow a full scientific evaluation, the applicant did not
reply. The Panel considers that no conclusions can be drawn from this study for the scientific
substantiation of the claim.
The Panel notes that no human studies have been provided from which conclusions can be drawn
for the scientific substantiation of the claim.
On the basis of the data provided, the Panel concludes that a cause and effect relationship has not
been established between the consumption of Vibigaba (germinated brown rice) and maintenance of
normal blood cholesterol concentration.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and specific requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health) which are based on newly developed
scientific evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientific substantiation of a health claim related to: Vibigaba (germinated brown rice)
and contribution to the maintenance of normal blood cholesterol concentration.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of Vibigaba, a positive assessment of its safety, nor a decision on whether Vibigaba is, or is
not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is Vibigaba (germinated
brown rice).
Health relationship as claimed by the applicant
According to the applicant, the claimed effect relates to: ‘contribution to the maintenance of normal
blood cholesterol levels. During the human intervention study provided, the changes of the blood
cholesterol levels were obtained. The conclusion of the study is that after three months of
intervention, cholesterol, triglycerides and LDL cholesterol decreased in the intervention group
compared with the control group, p > 0.05’.
Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
No information provided.
Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘contributes to the
maintenance of normal blood cholesterol levels’.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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Specific conditions of use as proposed by the applicant
According to the applicant, the target population for the intended health claim is adults with
metabolic syndrome between 55 and 70 years of age. The product should be used 100 g/meal,
2 meals/day for 3 months. Vibigaba should be cooked 45–60 min with the ratio between brown rice
and water 1/1.5. The rice should not be washed before cooking.
Data provided by the applicant
Health claim application on Vibigaba (germinated brown rice) and contribution to the maintenance
of normal blood cholesterol level and pursuant to Article 13.5 of Regulation 1924/2006, presented in a
common and structured format as outlined in the Scientific and technical guidance for the preparation
and presentation of applications for authorisation of health claims.2
As outlined in the General guidance for stakeholders on health claim applications,3 it is the
responsibility of the applicant to provide the totality of the available evidence.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientific requirements for health claims related to antioxidants, oxidative damage and
cardiovascular health are outlined in a specific EFSA guidance (EFSA NDA Panel, 2011).
3. Assessment
3.1. Characterisation of the food/constituent
The food proposed by the applicant as the subject of the health claim is Vibigaba (germinated
brown rice).
The nutritional composition of Vibigaba was provided. The content of protein, carbohydrate and fat
per 100 g of the uncooked product is 10.0 g, 72.1 g, and 3.6 g (0.8 g saturated fat, 1.6 g
monounsaturated fat and 1.2 g polyunsaturated fat), respectively. Vibigaba also contains dietary fibre
(3.9 g/100 g), sugars (< 0.2 g/100 g), sodium (20 mg/100 g), calcium (10 mg/100 g), vitamin B1
(0.24 mg/100 g) and vitamin E (1.0 mg/100 g). The Panel notes that batch-to-batch variability and
stability data were not provided.
The manufacturing process is described in the application. Fresh paddy (the whole plant) is dried
until maximum moisture of 15.5% is reached. Paddy is rinsed to eliminate impurities and then soaked
at a temperature of 28–30°C within 24–48 h to initiate the germination stage. After soaking, the germ
grows until it is 0.2 mm long (approximately for 24–36 h), then, it is dried, dehusked, sorted and
packed.
The Panel considers that the germinated brown rice Vibigaba, which is the subject of the health
claim, is sufficiently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘contribution to the maintenance of normal blood
cholesterol levels’. The proposed target population is ‘adults with metabolic syndrome’.
Low-density lipoproteins (LDLs) carry cholesterol from the liver to peripheral tissues, including the
arteries. Elevated LDL-cholesterol, by convention > 160 mg/dL (> 4.14 mmol/L), may compromise the
normal structure and function of the arteries. High-density lipoproteins (HDLs) act as cholesterol
scavengers and are involved in the reverse transport of cholesterol in the body (from peripheral tissues
back to the liver).
The Panel considers that maintenance of normal blood cholesterol concentration is a beneficial
physiological effect.
2 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2017. Scientific and technical guidance for the
preparation and presentation of an application for authorisation of a health claim (revision 1). EFSA Journal 2011;9(5):2170, 36
pp. https://doi.org/10.2903/j.efsa.2011.2170
3 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016. General scientific guidance for stakeholders
on health claim applications. EFSA Journal 2016;14(1):4367, 38 pp. https://doi.org/10.2903/j.efsa.2016.4367
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3.3. Scientific substantiation of the claimed effect
The applicant identified one human intervention study as being pertinent to the claim. The
Panel notes that the applicant did not perform a comprehensive literature search to identify human
intervention studies which could be pertinent to the claim other than the one provided by the
applicant. The applicant did not reply to a specific request from EFSA to provide this information.
In a randomised, two-arm, open-label, parallel study, Mai and Huong (2016), unpublished study
report) investigated the effects of Vibigaba germinated brown rice in subjects with metabolic syndrome
living in Vietnam.
A two-step procedure for the recruitment of eligible subjects was used. In the first step, subjects
aged 55–70 years with waist circumference > 90 cm (men) or > 80 cm (women) and arterial blood
pressure between 130/85 and 140/90 mmHg, who did not suffer from chronic diseases, were included.
In a second step, subjects having at least three out of the five National Cholesterol Education Program
Adult Treatment Panel (NCEP ATP III) diagnostic criteria for metabolic syndrome for Asian populations
were included.
Participants were randomly assigned to consume either Vibigaba germinated brown rice (100 g/meal,
2 meals daily) or the same amount of white rice (control group) for 3 months. Paired randomisation was
used, taking into account three age groups (55–59 years; 60–65 years and 66–70 years) and sex. The
Panel notes that no other information on the randomisation procedure used to allocate subjects to the
two study groups was provided.
All participants were instructed to consume rice as part of their usual diet, which should remain
unchanged throughout the study. Participants received Vibigaba every 10 days during the entire
intervention period (3 months). It is unclear from the study report whether white rice was provided to
the control group or not. Instructions for cooking the rice were provided to participants.
The quantity of rice consumed was recorded daily by the participants. The investigators checked
randomly the amount of rice available at the participants’ houses. All participants were asked to record
information related to their diet and physical exercise. Nutrient intakes were assessed by a
semiquantitative food frequency questionnaire (FFQ), which focused on foods rich in fibre,
carbohydrate and fat using the food composition tables for Vietnam. No other information was
provided about the characteristics of the FFQ (e.g. number of questions, validation, time period to
which it refers) or its use in the study (e.g. time of administration, self-administered vs dietitian
interview).
Information about medication use during the study was not provided.
The primary outcomes of the study were glycated haemoglobin (HbA1c), blood concentrations of
triglycerides and plasma malondialdehyde (MDA). Secondary outcome variables included body weight,
body mass index (BMI), waist circumference, arterial blood pressure, stool consistency, total
cholesterol, HDL-cholesterol, LDL-cholesterol, and fasting blood glucose and insulin, which were
measured at the start and at the end of the study.
Three separate sample size calculations were made, using a power of 80% and a < 0.05:
a) HbA1c, with an expected difference between the two groups at the end of the study of 0.23%
and a SD of the difference = 0.15%, n = 32 subjects per group;
b) blood concentrations of triglycerides, with an expected difference between the two groups of
0.4 mmol/L and a SD of the difference = 0.22 mmol/L, n = 34 subjects per group;
c) plasma MDA, with a difference between the two groups of 0.14 mmol/L and a SD of the
difference = 0.10 mmol/L, n = 25 subjects per group.
Allowing for a drop-out rate of 20%, the sample size needed in relation to the three primary
outcomes was specified as 80 participants (40 per group).
The Panel notes that changes in blood cholesterol concentrations (LDL-cholesterol and
HDL-cholesterol) were not a primary outcome of the study.
A Student’s t-test was used for statistical analysis of the results. Multiple testing was not considered in
data analysis. The Panel notes that the statistical analysis used is not appropriate for the study design.
While 976 subjects were screened, 86 subjects were randomised (n = 43 per group) and 80
participants (n = 40 per group) completed the study. Six subjects (three in the Vibigaba group and
three in the control group) dropped out ‘due to personal health reasons’. The Panel notes that the
results are reported for completers only and that information related to the treatment of missing data
was not provided.
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Upon a request from EFSA to provide additional information on the study which would allow a full
scientific evaluation, the applicant did not reply.
The Panel notes the important methodological limitations of the study (e.g. statistical analysis not
appropriate for the study design) and that the information provided on the design and conduct of the
study is insufficient for a complete scientific evaluation. The Panel considers that no conclusions can be
drawn from this study for the scientific substantiation of the claim.
The Panel notes that no human studies have been provided from which conclusions can be drawn
for the scientific substantiation of the claim.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of Vibigaba (germinated brown rice) and maintenance of normal cholesterol
concentrations.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, Vibigaba (germinated brown rice), which is the subject of the health
claim, is sufficiently characterised.
• The claimed effect proposed by the applicant is ‘contribution to the maintenance of normal
blood cholesterol levels’. The target population proposed by the applicant is ‘adults with
metabolic syndrome’. Maintenance of normal blood cholesterol concentration is a beneficial
physiological effect.
• A cause and effect relationship has not been established between the consumption of Vibigaba
(germinated brown rice) and maintenance of normal blood cholesterol concentration.
Steps taken by EFSA
Health claim application on ‘Vibigaba (germinated brown rice)’ and ‘maintenance of normal blood
cholesterol levels’ pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No:
0453_NL). Submitted by Loc Troi Group. 23 Ha Hoang Ho Street, Long Xuyen City, An Giang Province,
Vietnam represented by Etiketteren.nl, Vughterweg 47Q, 5211 CK Den Bosch, The Netherlands.
1) This application was received by EFSA on 9/1/2017.
2) The scope of the application was proposed to fall under a health claim based on newly
developed scientific evidence.
3) The scientific evaluation procedure started on 17/2/2017.
4) On 23/3/2017, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientific evaluation was suspended on 13/4/2017 and was restarted on 28/4/2017, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
5) During its meeting on 27/6/2017, the NDA Panel, having evaluated the data, adopted an
opinion on the scientific substantiation of a health claim related to Vibigaba (germinated
brown rice) and maintenance of normal blood cholesterol concentration.
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